Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2008

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Canaccord Adams 28th Annual Global Growth Conference in Boston on August 13, 2008 at 1:00 p.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
2. InterMune to Present at BMO Healthcare Conference
3. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
4. InterMune to Present at Jefferies Healthcare Conference
5. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
6. InterMune to Present at Citigroup Healthcare Conference
7. InterMune to Present at Bank of America Health Care Conference
8. InterMune to Present at Deutsche Bank Health Care Conference
9. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
10. Evotec Expands Collaboration With InterMune
11. InterMune to Present at the SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 08, 2020 , ... ... a significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES ... programs. , Bode-CARES provides a turnkey solution that includes a ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
(Date:7/7/2020)... ... 06, 2020 , ... R3 International is now offering stem cell therapy for ... cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with ... form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. ...
(Date:7/1/2020)... ... 2020 , ... MedShift , a leading medical technology ... obstacles created as a result of COVID-19. As a provider at the forefront ... and medical manufacturers by expanding access to device offerings, technology services, and marketing ...
Breaking Biology Technology:
(Date:8/21/2020)... ... August 19, 2020 , ... The 19th Annual ... science, data science, informatics and IT leaders goes VIRTUAL and announces its updated ... and change, Bio-IT takes the leadership role of keeping our life science community ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced ... for public health agencies of all sizes. With a focus on tracking symptoms ... find appropriate health care, Mosio helps public health departments automate communications and provide ...
(Date:8/5/2020)... ... ... Regenative Labs has received approval from the Centers for Medicare & Medicaid ... Wharton’s jelly allografts to be assigned a Q code and be approved for application ... jelly allograft product to be recognized as a 361 HCT/P by CMS regulated under ...
Breaking Biology News(10 mins):